{"groups":[{"description":"Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 1: Carfilzomib 15 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6","id":"FG000","title":"Cohort 1: Carfilzomib 15 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.\n\nCohort 2: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6","id":"FG001","title":"Cohort 2: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 2b: Carfilzomib 20 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5","id":"FG002","title":"Cohort 2b: Carfilzomib 20 mg/m2"},{"description":"Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.\n\nCohort 3b: Carfilzomib 27 mg/m2: Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5","id":"FG003","title":"Cohort 3: Carfilzomib 27mgm2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study was conducted using a standard 3+3 phase I design. If dose-limiting toxicity (DLT) occurred in 1 out of 3 patients, 3 additional patients were enrolled at that same dose level. Dose escalation was permitted if DLT did not occur in more than 0 out of 3, or 1 out of 6 patients"}